Guerbet signs agreement with Kyuan in China

by Spiren 0 comments



Pleased to share the news!

Guerbet (GBT) announced today the signing of an agreement with Beijing Kyuan Pharmaceutical Co., Ltd., one of the major pharmaceutical drugs distributors & importers in the Chinese market, to distribute & commercialize Lipiodol® Ultra-Fluid as from September 2015.

Founded in 1995, Kyuan is part of the Shanghai Pharma group (SPH) – China’s second biggest pharmaceutical distribution group – since 2011.

This agreement enables Guerbet flagship Interventional Radiology agent to benefit from Kyuan’s outstanding experience in distributing pharmaceuticals on the hospital market.


Marie-Claire Taine, Guerbet Group Commercial VP, commented: “We are looking forward to open new horizons in Interventional Oncology via this agreement with Kyuan, one of the country’s top drug distributors & one of the most reputed pharmaceutical partners throughout China, as we are determined to facilitate access for Chinese practitioners to the cTACE procedure which is standard-of-care across the world in interventional radiology”. Please click to get the full PR.


Comments are closed.